ClinicalTrials.gg
CompletedNCT00974974Updated Aug 11, 2020Results posted

A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).

A Phase 3 interventional study of IPX066 and IR CD-LD in Parkinson's Disease, sponsored by Impax Laboratories, LLC. Completed at 73 sites in 8 countries. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2020-08-11.

Sponsored by Impax Laboratories, LLC (part of Amneal Pharmaceuticals, Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
471
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc. — 1 open to participants now, 1 under way, none of them phase 3. Parkinson Disease · Amneal Pharmaceuticals, Inc..

Enrollment
3rd of 14
471 · median 77
Started
2009
with 1 other
Phase 3
7 of 14
none open now
Registered
6th of 14
by date

Among the 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc., this one is the 3rd largest by enrollment, is one of 2 that started in 2009, is one of 7 in phase 3, and was the 6th registered.

Parkinson Disease

4,580 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc. is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc., or all of them as a file.
02

Study summary

This is a study to evaluate the safety and efficacy of IPX066 in advanced Parkinson's disease.

Read the detailed description

A randomized, double-blind, active-control, parallel-group 13-week comparison of IPX066 versus regular carbidopa-levodopa (CD-LD). Prior to randomization, subjects on a stable regular LD regimen will enter a 3-week dose-adjustment period for IR CD-LD, followed by a 6-week dose-conversion period to IPX066.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

Keywords

  • Parkinson's Disease
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosed with idiopathic PD.
  2. At least 30 years old at the time of PD diagnosis.
  3. Currently being treated with IR LD (CD-LD or benserazide-LD) and on a stable regimen of IR LD for at least 4 weeks and:

    • Requiring a total daily IR LD dose of at least 400 mg
    • Having a minimum dosing frequency of four times per day.
  4. Able to differentiate "on" state from "off" state.
  5. Have predictable "off" periods.
  6. Amantadine, anticholinergics, selective monoamine oxidase (MAO) type B inhibitors (e.g., selegiline, rasagiline) or dopamine agonists are allowed as long as the doses and regimens have been stable for at least 4 weeks prior to Screening and the therapy is intended to be constant throughout the course of the study.
  7. Agrees to use a medically acceptable method of throughout the study and for 1 month afterward.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosed with atypical Parkinsonism or any known secondary Parkinsonian syndrome.
  2. Nonresponsive to LD therapy.
  3. Prior functional neurosurgical treatment for PD (e.g., ablation or deep brain stimulation) or if such procedures are anticipated during study participation.
  4. Received within 4 weeks or planning to take during participation in the clinical study: any controlled-release LD product, additional CD (e.g., Lodosyn®) or benserazide (e.g. Serazide®), catechol-O-methyl transferase inhibitors (e.g., entacapone and tolcapone), nonselective MAO inhibitors, apomorphine, and antipsychotics including neuroleptic agents for the purpose of treating psychosis or bipolar disorder.
  5. Allergic to Yellow Dye #5 (tartrazine).
  6. History of or currently active psychosis.
  7. Active or prior medical conditions such as peptic ulcers or prior surgical (e.g., bowel) procedures that would interfere with LD absorption.
  8. Active or history of narrow-angle glaucoma.
  9. A history of malignant melanoma or a suspicious undiagnosed skin lesion.
  10. History of myocardial infarction with residual atrial, nodal, or ventricular arrhythmias, upper gastrointestinal hemorrhage, or neuroleptic malignant syndrome and/or nontraumatic rhabdomyolysis.
  11. Received any medications during the 4 weeks prior to Screening.
  12. Unable to swallow large pills (e.g., large vitamin pills).
  13. Pregnant or breastfeeding.
  14. Subjects who are unable to complete a symptom diary.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
471 participants (actual)

Study arms

  • Experimental
    IPX066

    Following IR CD-LD dose adjustment and conversion to IPX066, subjects were assigned to Investigational product IPX066.

    Drug: IPX066 · Drug: IR CD-LD

  • Active comparator
    IR CD-LD

    Following IR CD-LD dose adjustment and conversion to IPX066, subjects were assigned to Investigational product IR CD-LD (active comparator).

    Drug: IPX066 · Drug: IR CD-LD

Interventions

  • DrugIPX066

    extended-release carbidopa-levodopa capsules

    Also known as: ER CD-LD

  • DrugIR CD-LD

    immediate-release carbidopa-levodopa tablets

    Also known as: immediate-release carbidopa-levodopa

06

What researchers measure

Primary outcomes

  1. Percentage of "Off" Time During Waking Hours at End of Study

    Percentage of "off" time during waking hours at end of study is measured by using the Parkinson's disease diary. "Off" time describes a period when the participant experiences increased Parkinsonian symptoms (e.g. immobility or inability to move with ease)."

    Time frame: 22 weeks

Secondary outcomes

  1. "Off" Time

    "Off" time hours is measured by using the Parkinson's disease diary. "Off" time describes a period when the participant experiences increased Parkinsonian symptoms (e.g. immobility or inability to move with ease)."

    Time frame: 22 weeks

  2. "On" Time Without Troublesome Dyskinesia

    "On" time without troublesome dyskinesiais measured by using the Parkinson's disease diary. "On" time without troublesome dyskinesia describes a period when the participant experiences decreased Parkinsonian symptoms (e.g. immobility or inability to move with ease) without dyskinesia (i.e. difficulty in performing voluntary movements) that affect daily living."

    Time frame: 22 weeks

07

Results

Posted Jan 14, 2016

Participant flow

Study period was form September 29, 2009 to January 19, 2011.

IR CD-LD Dose Adjustment
Participant flow — IR CD-LD Dose Adjustment
MilestoneIPX066IR CD-LD (Active Comparator)
Started0471
Completed0450
Not completed021
Withdrew: Adverse event03
Withdrew: Protocol violation01
Withdrew: Noncompliance with study drug01
Withdrew: Withdrawal by subject07
Withdrew: Various09
IPX066 Dose Conversion
Participant flow — IPX066 Dose Conversion
MilestoneIPX066IR CD-LD (Active Comparator)
Started4500
Completed3930
Not completed570
Withdrew: Adverse event230
Withdrew: Death20
Withdrew: Lack of efficacy130
Withdrew: Withdrawal by subject120
Withdrew: Various30
Withdrew: Protocol violation40
Maintenance - Double Blind Treatment
Participant flow — Maintenance - Double Blind Treatment
MilestoneIPX066IR CD-LD (Active Comparator)
Started201192
Completed186182
Not completed1510
Withdrew: Adverse event33
Withdrew: Protocol violation11
Withdrew: Noncompliance with study drug01
Withdrew: Lack of efficacy22
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject52
Withdrew: Various40

Outcome measures

PrimaryPercentage of "Off" Time During Waking Hours at End of Study

Percentage of "off" time during waking hours at end of study is measured by using the Parkinson's disease diary. "Off" time describes a period when the participant experiences increased Parkinsonian symptoms (e.g. immobility or inability to move with ease)."

Time frame:
22 weeks
Reported as:
Mean · percentage
Percentage of "Off" Time During Waking Hours at End of Study
percentageIPX066IR CD-LD (Active Comparator)
Percentage of "Off" Time During Waking Hours at End of Study23.82 ± 14.9129.79 ± 15.81
Statistical analysis
  • IR CD-LD (Active Comparator) · ANCOVA · p = <.0001
Secondary"Off" Time

"Off" time hours is measured by using the Parkinson's disease diary. "Off" time describes a period when the participant experiences increased Parkinsonian symptoms (e.g. immobility or inability to move with ease)."

Time frame:
22 weeks
Reported as:
Mean · hours
"Off" Time
hoursIPX066IR CD-LD (Active Comparator)
"Off" Time3.87 ± 2.464.88 ± 2.71
Statistical analysis
  • IR CD-LD (Active Comparator) · ANCOVA · p = <.0001
Secondary"On" Time Without Troublesome Dyskinesia

"On" time without troublesome dyskinesiais measured by using the Parkinson's disease diary. "On" time without troublesome dyskinesia describes a period when the participant experiences decreased Parkinsonian symptoms (e.g. immobility or inability to move with ease) without dyskinesia (i.e. difficulty in performing voluntary movements) that affect daily living."

Time frame:
22 weeks
Reported as:
Mean · hours
"On" Time Without Troublesome Dyskinesia
hoursIPX066IR CD-LD (Active Comparator)
"On" Time Without Troublesome Dyskinesia11.84 ± 2.9610.91 ± 2.82

Adverse events

Collected over 22 weeks. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IPX066—11/201 (5.5%)57/201 (28.4%)
Carbidopa-Levodopa—5/192 (2.6%)50/192 (26%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventIPX066Carbidopa-Levodopa
Atrial FibrillationCardiac disorders0/2011/192
Chest PainGeneral disorders0/2011/192
OsteomyelitisInfections and infestations0/2011/192
PneumoniaInfections and infestations0/2011/192
Subdural HematomaInjury, poisoning and procedural complications0/2011/192
Intervertebral Disc DegenerationMusculoskeletal and connective tissue disorders0/2011/192
Respiratory FailureRespiratory, thoracic and mediastinal disorders0/2011/192
Toe AmputationSurgical and medical procedures0/2011/192
Acute Myocardial InfarctionCardiac disorders1/2010/192
Small Intestinal ObstructionGastrointestinal disorders1/2010/192
Most frequent other events
Showing 10 of 27
Most frequent other events
EventIPX066Carbidopa-Levodopa
InsomniaPsychiatric disorders7/2012/192
nauseaGastrointestinal disorders6/2013/192
FallInjury, poisoning and procedural complications6/2014/192
DepressionPsychiatric disorders1/2015/192
DizzinessNervous system disorders5/2012/192
DyskinesiaNervous system disorders5/2012/192
Oedema PeripheralGeneral disorders4/2014/192
Upper Respiratory Tract InfectionInfections and infestations4/2014/192
Urinary Tract InfectionInfections and infestations4/2014/192
Sleep DisorderPsychiatric disorders4/2014/192

Baseline characteristics

All treated

Age, Continuous
Age, Continuous(years)IPX066Carbidopa-LevodopaTotal
Mean63.1 ± 10.063.4 ± 8.863.2 ± 9.4
Sex: Female, Male
Sex: Female, Male(Participants)IPX066Carbidopa-LevodopaTotal
Female7267139
Male129125254
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)IPX066Carbidopa-LevodopaTotal
Hispanic or Latino3811
Not Hispanic or Latino192182374
Unknown or Not Reported628
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)IPX066Carbidopa-LevodopaTotal
White196186382
Black or African American213
Asian112
American Indian or Alaskan Native022
Other123
Unknown101
Region of Enrollment
Region of Enrollment(participants)IPX066Carbidopa-LevodopaTotal
Canada10818
Romania347
United States9893191
Ukraine373875
Poland343367
France213
Germany121123
Spain549
08

Study locations

73 sites
  • Investigator 17
    Birmingham, Alabama 35233, United States
  • Investigator 49
    Phoenix, Arizona 85013, United States
  • Investigator 7
    Little Rock, Arkansas 72205, United States
  • Investigator 3
    La Jolla, California 92037, United States
  • Investigator 31
    Sunnyvale, California 94085, United States
  • Investigator 6
    Torrance, California 90502, United States
  • Investigator 51
    Aurora, Colorado 80045, United States
  • Investigator 10
    New Haven, Connecticut 06510, United States
  • Investigator 64
    Bradenton, Florida 34205, United States
  • Investigator 61
    Hollywood, Florida 33021, United States
  • Investigator 5
    Ocala, Florida 34471, United States
  • Investigator 15
    Port Charlotte, Florida 33980, United States
  • Investigator 8
    Port Charlotte, Florida 33980, United States
  • Investigator 4
    Saint Petersburg, Florida 33713, United States
  • Investigator 46
    Augusta, Georgia 30912, United States
  • Investigator 38
    Boise, Idaho 83702, United States
  • Investigator 19
    Chicago, Illinois 60611, United States
  • Investigator 40
    Chicago, Illinois 60612, United States
  • Investigator 39
    Des Moines, Iowa 50309, United States
  • Investigator 29
    Kansas City, Kansas 66160, United States
  • Investigator 1
    Bingham Farms, Michigan 48025, United States
  • Investigator 21
    New Brunswick, New Jersey 08901, United States
  • Investigator 25
    Albany, New York 12208, United States
  • Investigator 8
    Commack, New York 11725, United States
  • Investigator 12
    New York, New York 10032, United States
  • Investigator 11
    Durham, North Carolina 27707, United States
  • Investigator 9
    Raleigh, North Carolina 27607, United States
  • Investigator 20
    Cincinnati, Ohio 45219, United States
  • Investigator 42
    Toledo, Ohio 43614, United States
  • Investigator 60
    Tulsa, Oklahoma 74137, United States
  • Investigator 14
    Charleston, South Carolina 29401, United States
  • Investigator 16
    Dallas, Texas 75390-9016, United States
  • Investigator 13
    Houston, Texas 77030-2744, United States
  • Investigator 65
    Tacoma, Washington 98405, United States
  • Investigator 2
    Milwaukee, Wisconsin 53233, United States
  • Investigator 24
    London, Ontario N6A 5A5, Canada
  • Investigator 18
    Ottawa, Ontario K1G 4G3, Canada
  • Investigator 26
    Quebec, G1R 3X5, Canada
  • Investigator 32
    Strasbourg Cedex, Alsace 67091, France
  • Investigator 22
    Dijon, Bourgogne 21000, France
  • Investigator 58
    Paris, Ile-de-france 75013, France
  • Investigator 33
    Toulouse, Midi-pyrenees 31059, France
  • Investigator 52
    Lille, NORD Pas-de-calais 59037, France
  • Investigator 30
    Sachsen, Dresden 1307, Germany
  • Investigator 27
    Westerstede, Niedersachsen 26655, Germany
  • Investigator 23
    Berlin, 10437, Germany
  • Investigator 72
    Berlin, 12163, Germany
  • Investigator 28
    Berlin, 13088, Germany
  • Investigator 67
    Berlin, 13353, Germany
  • Investigator 48
    Bydgoszcz, Kujawsko-pomorskie 85-796, Poland
  • Investigator 59
    Lublin, Lubelskie 20-718, Poland
  • Investigator 37
    Kraków, Malopolskie 31-530, Poland
  • Investigator 36
    Warszawa, Mazowieckie 02-777, Poland
  • Investigator 35
    Mosina, Wielkopoloskie 62-050, Poland
  • Investigator 54
    Szczecin, Zachodniopomorskie 70-215, Poland
  • Investigator 34
    Katowice, 40-546, Poland
  • Investigator 69
    Târgu-Mureş, Mures 540136, Romania
  • Investigator 68
    Brasov, 500283, Romania
  • Investigator 62
    Bucuresti, 20125, Romania
  • Investigator 63
    Târgu Mureş, 540136, Romania
  • Investigator 43
    Terrassa, Barcelona 8221, Spain
  • Investigator 70
    Barcelona, 8028, Spain
  • Investigator 57
    Barcelona, 8036, Spain
  • Investigator 45
    Barcelona, 8190, Spain
  • Investigator 50
    Madrid, 28006, Spain
  • Investigator 53
    Madrid, 28922, Spain
  • Investigator 55
    Dnepropetrovsk, Dnipropetrovsk 49005, Ukraine
  • Investigator 56
    Vinnitsa, Vinnytsya 21005, Ukraine
  • Investigator 47
    Zaporozhye, Zaporizhzhya 69600, Ukraine
  • Investigator 71
    Donetsk, 83003, Ukraine
  • Investigator 44
    Kharkiv, 61068, Ukraine
  • Investigator 66
    Odessa, 65117, Ukraine
  • Investigator 41
    Zaporozhye, 69035, Ukraine
09

References and documents

Publications

  • Morgan JC, Dhall R, Rubens R, Khanna S, Gupta S. Dosing Patterns during Conversion to IPX066, Extended-Release Carbidopa-Levodopa (ER CD-LD), in Parkinson's Disease with Motor Fluctuations. Parkinsons Dis. 2018 Oct 22;2018:9763057. doi: 10.1155/2018/9763057. eCollection 2018. PubMed 30425824 ↗
  • Hauser RA, Hsu A, Kell S, Espay AJ, Sethi K, Stacy M, Ondo W, O'Connell M, Gupta S; IPX066 ADVANCE-PD investigators. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol. 2013 Apr;12(4):346-56. doi: 10.1016/S1474-4422(13)70025-5. Epub 2013 Feb 26. PubMed 23485610 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2009, a primary completion of Jan 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2016, 5 years after primary completion. A results delay was requested in Sep 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2009
First posted
Sep 11, 2009
Start
Sep 2009
Primary completionActual
Jan 2011
CompletionActual
Mar 2011
Results delay requested
Sep 27, 2013
Results first posted
Jan 14, 2016
Last update
Aug 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00974974
Responsible party
Sponsor
First posted
Sep 11, 2009
Start date
Sep 2009
Primary completion
Jan 2011
Completion
Mar 2011
Results posted
Jan 14, 2016
Last update
Aug 11, 2020

Study contacts

Impax Study Director
study director · Impax Laboratories, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion